To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Reduction in Odds of Pathological Fracture with Denosumab vs Zoledronic Acid for Bone Metastases

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
October 2020

Reduction in Odds of Pathological Fracture with Denosumab vs Zoledronic Acid for Bone Metastases

Vol: 9| Issue: 10| Number:7| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials.

J Am Acad Orthop Surg Glob Res Rev. 2020 Aug; 4(8): e20.00045.

Contributing Authors:
H Al Farii A Frazer L Farahdel F AlFayyadh R Turcotte

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Four studies including 7320 patients with bone metastases from advanced cancer were included in this meta-analysis comparing the likelihood of pathological fracture. Sub-group analyses were performed by tumour origin (endodermal cancer, mesodermal cancer). Pooled results found the likelihood of pathological fracture to be significantly lower in the denosumab group compared to the zoledronic acid g...

Join the Conversation

Please Login or Join to leave comments.